Daxor Co. (NASDAQ:DXR) Sees Large Decrease in Short Interest

Daxor Co. (NASDAQ:DXR) was the recipient of a significant decline in short interest in March. As of March 31st, there was short interest totalling 10,600 shares, a decline of 17.8% from the March 15th total of 12,900 shares. Based on an average daily trading volume, of 7,100 shares, the short-interest ratio is presently 1.5 days. Approximately 0.5% of the shares of the stock are short sold.

Daxor Stock Down 1.2 %

Daxor stock traded down $0.09 during midday trading on Friday, hitting $7.41. 2,392 shares of the stock were exchanged, compared to its average volume of 6,835. Daxor has a 52 week low of $6.55 and a 52 week high of $10.00. The company has a fifty day simple moving average of $7.72 and a two-hundred day simple moving average of $8.27.

Insider Buying and Selling at Daxor

In other news, CEO Michael Richard Feldschuh bought 3,360 shares of the stock in a transaction dated Monday, March 10th. The stock was bought at an average cost of $7.68 per share, with a total value of $25,804.80. Following the purchase, the chief executive officer now owns 210,852 shares of the company’s stock, valued at approximately $1,619,343.36. This represents a 1.62 % increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is available at the SEC website. Insiders have bought a total of 6,423 shares of company stock worth $50,082 over the last ninety days. Corporate insiders own 59.00% of the company’s stock.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in Daxor stock. Renaissance Technologies LLC lifted its holdings in Daxor Co. (NASDAQ:DXR) by 87.7% in the 4th quarter, according to its most recent 13F filing with the SEC. The firm owned 27,821 shares of the company’s stock after purchasing an additional 13,000 shares during the quarter. Renaissance Technologies LLC owned about 0.57% of Daxor worth $214,000 as of its most recent SEC filing. Institutional investors and hedge funds own 1.34% of the company’s stock.

Analyst Upgrades and Downgrades

Separately, Ascendiant Capital Markets upped their target price on shares of Daxor from $24.75 to $25.00 and gave the company a “buy” rating in a research report on Monday, March 17th.

About Daxor

Daxor Corporation, a medical device company, provides blood volume measurement technology focused on blood volume testing. The company develops and markets BVA-100 Blood Volume Analyzer, a diagnostic blood test to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms for used in a broad range of medical and surgical conditions.